Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase
II(b) Trial for Cocaine Addiction

CORAL GABLES, Fla., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX) today announced top-line results from its U.S.
Phase II(b) clinical trial evaluating the use of CPP-109 (vigabatrin) to treat
cocaine addiction. The data from the trial showed that CPP-109 did not meet
the primary endpoint -- that a significantly larger proportion of
CPP-109-treated subjects than placebo-treated subjects were cocaine-free
during the last two weeks of the treatment period (Weeks 8 and 9). The data
also showed that the two key secondary endpoints, a significantly larger
increase in cocaine negative urines and a significant decrease in the weekly
fraction of use days in medication-treated subjects during weeks 3-9, also
were not met. The clinical trial did not reveal any unexpected "serious"
adverse events.

Catalyst expects the remaining protocol-specified analyses for other secondary
and exploratory clinical endpoints and safety data to be completed during the
first half of next year, after all the follow-up clinical data have been
received to be able to fully unblind the trial data.

Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer,
commented, "We are obviously very disappointed with the top-line results from
our Phase II(b) cocaine trial, particularly given the changes that were
incorporated into the protocol for this trial to ensure maximum medication
compliance from a more motivated patient population. Once we have the full
data set, we will meet with our collaborator on the Phase II(b) trial, the
National Institute of Drug Abuse (NIDA), to determine next steps, if any, in
the clinical development program for CPP-109 for cocaine addiction."

Mr. McEnany continued, "In the near term, we intend to focus all of our
efforts on the development of our two other product candidates: Firdapse^TM
for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and CPP-115 for
the treatment of infantile spasms. Both of these product candidates have
received orphan drug designation and are intended to treat a rare neurological
disorder. We will also monitor the results of the ongoing
investigator-sponsored study evaluating the use of CPP-109 for the treatment
of Tourette's Disorder to determine whether we should pursue future studies of
CPP-109 with respect to that orphan indication."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty
pharmaceutical company focused on the development and commercialization of
prescription drugs targeting diseases and disorders of the central nervous
system. Catalyst has three products in development, CPP-109 (vigabatrin, a
GABA aminotransferase inhibitor), which Catalyst plans to develop for the
treatment of cocaine addiction and Tourette's Disorder, CPP-115, another GABA
aminotransferase inhibitor that is more potent than vigabatrin and has reduced
side effects (e.g., visual field defects, or VFDs) from those associated with
vigabatrin, which Catalyst plans to develop for the treatment of drug
addiction and epilepsy (primarily infantile spasms) and Firdapse^TM, which
Catalyst plans to develop for commercialization in North America as a
treatment for LEMS. For additional information, please visit
www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether CPP-109 will be
determined to be an effective treatment for cocaine addiction and Tourette's
Disorder, whether CPP-115 will be determined to be an effective treatment for
its targeted indications, whether Firdapse™ will be determined to be an
effective treatment for LEMS or other diseases, whether Catalyst will ever
receive an approval of an NDA for any of its product candidates, whether
Catalyst will ever be in a position to commercialize any of its product
candidates, and those other factors described in Catalyst's filings with the
U.S. Securities and Exchange Commission (SEC), could adversely affect the
forward-looking statements contained in this press release. Copies of
Catalyst's filings with the SEC are available from the SEC, may be found on
Catalyst's website or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information contained herein,
which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com